Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
Josep Maria PiulatsEnrique EspinosaLuis de la Cruz MerinoMar VarelaLorenzo Alonso CarriónSalvador Martín-AlgarraRafael López-CastroTeresa CurielDelvys Rodríguez-AbreuMiriam RedradoMontserrat GomàAntonio José RullánAlfonso Calvo GonzálezAlfonso Berrocal-JaimePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.